Last reviewed 2026-04-23 · How we verify

Cohort 1 neo-adjuvant

This drug targets the PD-1 receptor to inhibit cancer cell growth.

This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Unresectable or metastatic melanoma, Locally advanced or metastatic non-small cell lung cancer, Locally advanced or metastatic renal cell carcinoma.

At a glance

Mechanism of action

By binding to PD-1, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially slows or stops cancer progression.

Approved indications

• Unresectable or metastatic melanoma
• Locally advanced or metastatic non-small cell lung cancer
• Locally advanced or metastatic renal cell carcinoma

Common side effects

• Pneumonitis
• Colitis
• Hypothyroidism
• Hyperthyroidism
• Fatigue
• Diarrhea
• Nausea
• Vomiting
• Rash
• Pruritus

Key clinical trials

• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (PHASE2)
• Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (PHASE2)
• Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (PHASE2)
• Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 (NA)
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer (PHASE1)
• Excision of Lymph Node Trial (EXCILYNT) (Mel69) (NA)
• A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 (PHASE1)
• Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.